ERBB2 and neoplasm: A recent study revealed that FASN has a higher expression in the HER2 positive subgroup than the HER2 negative group, and its inhibitor could prevent the agonistic tumor-promoting activity of tamoxifen and restore its estrogen antagonist properties against ER/HER2- positive xenograft tumors in mice [30].